Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor

Terrence L. Cascino, Michael H. Veeder, Jan C. Buckner, Judith R. O'Fallon, Martin Wiesenfeld, Ralph Levitt, Richard M. Goldberg, Steven A. Kuross, Roscoe F. Morton, Bernd W. Scheithauer

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Thirty patients with recurrent primary brain tumors were treated with a combination of 5-fluorouracil and leucovorin. There were three responses seen. Toxicity consisted of stomatitis, diarrhea, and hematological suppression. 5-fluorouracil and leucovorin would appear to be minimally effective in recurrent brain tumors.

Original languageEnglish (US)
Pages (from-to)243-246
Number of pages4
JournalJournal of neuro-oncology
Volume30
Issue number3
DOIs
StatePublished - Jan 1 1996

Keywords

  • 5-fluorouracil
  • Astrocytoma
  • Leucovorin
  • Oligodendroglioma
  • Radiation therapy
  • Recurrent glioma

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor'. Together they form a unique fingerprint.

  • Cite this

    Cascino, T. L., Veeder, M. H., Buckner, J. C., O'Fallon, J. R., Wiesenfeld, M., Levitt, R., Goldberg, R. M., Kuross, S. A., Morton, R. F., & Scheithauer, B. W. (1996). Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. Journal of neuro-oncology, 30(3), 243-246. https://doi.org/10.1007/BF00177275